Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 16/20 | 0.52 |
| ▸ | PTPN2 | P17706 | 8/20 | 0.52 |
| ▸ | PTPRC | P08575 | 2/20 | 0.46 |
| ▸ | PGK1 | P00558 | 1/20 | 0.41 |
| ▸ | PGK2 | P07205 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4862253 | 0.99 | PTPN1 (0.53) | PTPN1PTPN2PTPRCPGK1PGK2 | |
| Bromide SCHEMBL3735944 | 0.86 | PTPN1 (0.49) | PTPN1PTPN2PTPRC | |
| SCHEMBL4119714 | 0.85 | PTPN1 (0.50) | PTPN1PTPN2PTPRC | |
| SCHEMBL3742965 | 0.84 | PTPN1 (0.56) | PTPN1PTPN2PTPRCPGK1PGK2 | |
| SCHEMBL3738325 | 0.81 | PTPN1 (0.56) | PTPN1PTPN2PTPRCPGK1PGK2 | |
| SCHEMBL3732880 | 0.80 | PTPN1 (0.41) | PTPN1PTPN2PTPRC | |
| SCHEMBL27715887 | 0.80 | PTPN1 (0.55) | PTPN1PTPN2PTPRCPGK1PGK2 | |
| SCHEMBL3732885 | 0.80 | PTPN1 (0.41) | PTPN1PTPN2PTPRC | |
| Bromide SCHEMBL3748691 | 0.78 | PTPN1 (0.53) | PTPN1PTPN2PTPRCPGK1PGK2 | |
| SCHEMBL7659253 | 0.78 | PTPN1 (0.70) | PTPN1PTPN2PTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829737-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | CEPTYR, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090131374-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CEPTYR, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-7504389-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | CEPTYR, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080161592-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CEPTYR, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20060142250-A1 | Protein tyrosine phosphatase inhibitors and methods of use thereof | FALCON TECHNOLOGY PARTNERS L.P. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161592-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PPM1B, PTPN1, PTPN5 | PTPN1 2/4885PTPN2 5/4885PTPRC 21/4885 |
| US-20060142250-A1 | Protein tyrosine phosphatase inhibitors and methods of use thereof | PPM1B, PTPN1, PTPN5 | PTPN1 2/4885PTPN2 5/4885PTPRC 21/4885 |
| US-20090131374-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PPM1B, PTPN1, PTPN5 | PTPN1 2/4885PTPN2 5/4885PTPRC 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.